New study tests the safety and efficacy of combination therapy in adults with astrocytoma and glioblastoma

Glioblastoma (GBM)

A two-part clinical trial of a multikinase inhibitor plus chemotherapy in patients with two types of brain tumors is enrolling in Bethesda, MD. The study will be open to patients with anaplastic astrocytoma, an uncommon malignant brain tumor that develops from star-shaped brain cells called astrocytes and glioblastoma, the most common and aggressive form of astrocytoma. The combination therapy includes Temozolomide, a chemotherapy drug used to treat some brain cancers and TG02, a multikinase inhibitor, a type of drug that blocks overactive enzymes and certain cellular functions that promote tumor growth. Clinical trial lead physician Dr. Jing Wu, of CCR's Neuro-Oncology Branch wants to find the safest dose of temozolomide and TG02, and then see if this combination can help patients with brain tumors that have not responded to other treatments. View more information on this trial.

Summary Posted: Thu, 12/01/2016